Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective

Annals of Indian Academy of Neurology

Volumn 11, Issue 4, 2008, Pages 231-235

  Sharma, S ^a,b   Sharma, Nalini ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b NORTH EASTERN INDIRA GANDHI REGIONAL INSTITUTE OF HEALTH AND MEDICAL SCIENCES   (India)

Author keywords

Aldolase reductase inhibitor; Diabetes; Peripheral neuropathy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EPALRESTAT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EDEMA; FEMALE; HUMAN; HYPESTHESIA; KIDNEY FUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MOTOR NERVE CONDUCTION; NAUSEA; PARESTHESIA; SENSORY NERVE CONDUCTION; SIDE EFFECT; STOMACH DISEASE; VOMITING;

EID: 58149173782     PISSN: 09722327     EISSN: 19983549     Source Type: Journal    
DOI: 10.4103/0972-2327.44558     Document Type: Article

References (18)

1. Terashima H, Hama K, Yamomoto R, Tsuboshima M, Kikkawa R, Hatanaka I, et al. Effects of a new aldose reductase inhibitor on various tissue in vitro. J Pharamacol Exp Ther 1984;229:226-30.
2. Hotta N, Sakamoto N. Aldose reductase inhibitors. In: Alberti KG, Krall LP, editors. The diabetes Annual vol. 5. Amsterdam: Elsevier Science Publishers BV; 1990. p. 330-61.
3. Steele JW, Faulds D, Goa KL. Epalrestat: A review of its pharmacology and therapeutic potential in late-onset complications of diabetes mellitus. Drug Aging 1993;3:532-55.
4. Hotta, N, Kakuta H, Fukasawa H, Kimura M, Koh N, Iida M, et al. Effects of a fructose -rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin treated rats. Diabetologia 1985;28:176-80.
5. Hotta N, Sugimura K, Kakuta H, Fukasawa H, Kimura M, Koh N, et al. Effects of a fructose rich diet and an aldose reductase inhibitor on the development of diabetic neuropathy in streptozotocin-treated rats. In: Sakamoto N, Kinoshita JH, Kador PF, Hotta N, editors. Polyol pathway and its role in diabetic complications. Amsterdam: Elsevier Science Publishers BV; 1988. p. 511.
6. Hotta N. New concepts and insights on pathogenesis and treatment of diabetic complications: Polyol pathway and its inhibition. Nagoya J Med Sci 1997;60:89-100.
7. Oates PJ, Mylari BL. Aldose reductase inhibitors: Therapeutic implications for diabetic complications. Expert Opin Investig Drugs 1999;8:2095-119.
8. Cameron NE, Eaton SE, Cotter MA, Tesfaye S: Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001;44:1973-88.
9. Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 2002;50:325-92.
10. Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kikkawa R. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy: Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed Pharmacother 1995;49:269-77.
11. Hotta N, Sakamoto N, Shigeta Y, Kikkawa R, Goto Y; Diabetic Neuropathy Study Group in Japan. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: Multicenter study. J Diabetes Compl 1996;10:168-72.
12. Boulton AJ. Treatments for diabetic neuropathy. Curr Diab Rep 2001;1:127-32.
13. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:89-94.
14. Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: A 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001;24:1776-82.
15. Greene DA, Arezzo JC, Brown MB; Zenarestat Study Group. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology 1999;53:580-91.
16. Bril V, Buchanan RA; the AS-3201 Study Group. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2004;27:2369-75.
17. Bril V, Buchanan RA; the Ranirestat Study Group. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006;29:68-72.
18. Sakakibara H, Hirata M, Hashiguchi T, Toibana N, Koshiyama H, Zhu SK, et al. Digital sensory nerve conduction velocity and vibration perception threshold in peripheral neurological test for hand-arm vibration syndrome. Am J Ind Med 1996;30:219-24.